CKD Specific Telemonitoring Platform to Minimize Adverse Outcomes in High Risk CKD Patients
A Pragmatic Randomized Controlled Trial of a CKD Specific Telemonitoring Platform to Minimize Adverse Outcomes in High Risk CKD Patients
University of Manitoba
340 participants
Jun 30, 2022
INTERVENTIONAL
Conditions
Summary
The main purpose of this trial is to determine whether the addition of the VIEWER virtual care platform to usual care will lead to a reduction in composite emergency department (ED) visits and/or hospitalizations/or increase the perceived safety of virtual care among patients and providers.
Eligibility
Inclusion Criteria6
- \>18 years of age
- Patient or primary caregiver can read and speak English
- Patient or patients substitute decision maker is able to provide informed consent
- Patient or primary care giver cognitively and physically capable and willing to use the VIEWER mobile application and perform self-measurements (i.e. weight, BP, etc.)
- Have stage 5 CKD (2 measurements of eGFR \<15ml/min/1.73m2); eGFR will be calculated with the CKD-EPI equation, or have \>40% chance of beginning dialysis in the next 2 years based on the Kidney Failure Risk Equation
- Followed in a multidisciplinary CKD clinic
Exclusion Criteria1
- Inability of self or caregiver assisted self-monitoring using VIEWER
Interventions
VIEWER is a tablet based, CKD specific home telemonitoring platform developed by our team of patients and researchers that integrates data from a wireless blood pressure cuff, weigh scale, transcutaneous O2 sat monitor and wearable motion tracker via a tablet and custom app.
Locations(5)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05726526